PRIMARY INTRAVITREAL BEVACIZUMAB FOR SUBFOVEAL CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION: Results of the Pan-American Collaborative Retina Study Group at 12 Months Follow-up

@article{Arevalo2008PRIMARYIB,
  title={PRIMARY INTRAVITREAL BEVACIZUMAB FOR SUBFOVEAL CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION: Results of the Pan-American Collaborative Retina Study Group at 12 Months Follow-up},
  author={J. Fernando Arevalo and Jans Fromow-Guerra and Juan Gonzalo S{\'a}nchez and Maur{\'i}cio Maia and Mar{\'i}a H. Berrocal and Lihteh Wu and Mario Joaqu{\'i}n Saravia and Rog{\'e}rio Alves Costa},
  journal={Retina},
  year={2008},
  volume={28},
  pages={1387-1394}
}
Purpose: To report the 12-month anatomic and Early Treatment Diabetic Retinopathy Study best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin™, Genentech Inc., San Francisco, CA) (1.25 mg or 2.5 mg) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Methods: Sixty-three eyes of 63 consecutive patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration, a mean age of… Expand
Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study.
TLDR
The results show no significant difference regarding BCVA with IVB at doses of 1.25 or 2.5 mg, which seems to provide stability or improvement in BCVA, OCT, and FA in subfoveal CNV secondary to AMD at 24 months. Expand
Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study.
TLDR
Eyes with neovascular AMD treated with intravitreal bevacizumab over 12 months had significant anatomical and functional improvement and further studies need to confirm the long-term efficacy of this treatment. Expand
INTRAVITREAL BEVACIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION: Effect on Different Subfoveal Membranes
TLDR
After an intravitreal application of bevacizumab given as therapy for exudative age-related macular degeneration at 2-month intervals, the patient's gain in visual acuity did not depend on the type of the subfoveal neovascular membranes. Expand
VISUAL OUTCOMES AND GROWTH FACTOR CHANGES OF TWO DOSAGES OF INTRAVITREAL BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Randomized, Controlled Trial
TLDR
Baseline aqueous vascular endothelial growth factor level might have a role in predicting angiographic response after bevacizumab injections, and three monthly intravitreal 1.25-mg and 2.5-mg injections seemed to result in better visual outcome than 2. Expand
RETREATMENT WITH ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY BASED ON CHANGES IN VISUAL ACUITY AFTER INITIAL STABILIZATION OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: 3-Year Follow-up Results
TLDR
After stabilization of the disease, a monthly follow-up of optical coherence tomography and re-treatment based on morphologic, clinical, and vision outcomes may increase the efficacy in patients with neovascular related macular degeneration under anti–vascular endothelial growth factor treatment. Expand
Retrospective study of an as required dosing regimen of intravitreal bevacizumab in neovascular age-related macular degeneration in an Australian population
TLDR
Eyes with neovascular AMD treated with intravitreal bevacizumab for up to 12 months had significant functional and anatomical improvement, and further studies need to confirm the long-term safety and efficacy of this treatment. Expand
Intravitreal injection of triamcinolone combined with bevacizumab for choroidal neovascularization associated with large retinal pigment epithelial detachment in age-related macular degeneration
TLDR
Combined IVB and IVTA therapy seems to be an effective and safe procedure to treat CNV associated with large PED in AMD. Expand
Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
TLDR
Bvacizumab was noninferior to ranibizumAB for visual acuity at 1 year with similar safety profiles, and Ranibizuab tended to have a better anatomic outcome. Expand
Intravitreal Ranibizumab versus Thermal Laser Photocoagulation in the Treatment of Extrafoveal Classic Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
TLDR
Intravitreal ranibizumab showed promising results in BCVA improvement and decrease in macular thickness in patients with extrafoveal classic CNV due to AMD, with a small number of injections. Expand
An intravenous microdose of bevacizumab for the treatment of pigment epithelial detachment associated to age-related macular degeneration refractory to intravitreal bevacizumab: a case report.
TLDR
An intravenous injection of a microdose of bevacizumab appears to have resolved the PED with a sustained improvement of visual acuity. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 43 REFERENCES
INTRAVITREAL BEVACIZUMAB TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION
TLDR
A retrospective study of patients with CNV secondary to AMD who were treated with intravitreal injection of bevacizumab during a 3-month period found no apparent short-term safety concerns and treated eyes had a significant decrease in macular thickness and improvement in visual acuity. Expand
VISUAL IMPROVEMENT FOLLOWING INTRAVITREAL BEVACIZUMAB (AVASTIN) IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION
TLDR
Intravitreal bevacizumab has the potential for improvement in vision in both naive and previously treated eyes for at least 6 months, and the benefit is more pronounced in eyes without prior pegaptanib and/or PDT. Expand
Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration.
TLDR
Eyes with CNV due to AMD treated with intravitreal bevacizumab had marked anatomic and visual improvement, and further studies are necessary to confirm the long-term efficacy and safety of this treatment. Expand
Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
TLDR
Short-term results suggest that intravitreal bevacizumab (1.25 mg) is well tolerated and associated with improvement in VA, decreased retinal thickness by OCT, and reduction in angiographic leakage in most patients, the majority of whom had previous treatment with photodynamic therapy and/or pegaptanib. Expand
INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT OF MACULAR EDEMA IN CENTRAL RETINAL VEIN OCCLUSION: A Short-Term Study
TLDR
Initial treatment results of patients with macular edema secondary to CRVO did not reveal any short-term safety concerns and visual acuity improvement, defined as a halving of the visual angle, was seen in 14 of the 16 eyes. Expand
Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study.
TLDR
Overall, bevacizumab therapy was well tolerated, with an improvement in VA, OCT, and angiographic outcomes, and although these preliminary results are promising, a randomized controlled clinical trial is necessary before concluding that systemic bevicizumAB therapy is safe and effective for patients with neovascular AMD. Expand
INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT OF PROLIFERATIVE DIABETIC RETINOPATHY COMPLICATED BY VITREOUS HEMORRHAGE
TLDR
Intravitreal bevacizumab resulted in marked regression of neovascularization and rapid resolution of vitreous hemorrhage and the favorable short-term results suggest further study is needed in a larger group of patients. Expand
Intravitreal bevacizumab for exudative age-related macular degeneration after multiple treatments
TLDR
The chronic retinal and pigment epithelium changes frequently present in eyes that underwent multiple previous treatments may limit complete visual recovery, and short-term results with IVB for the treatment of exudative AMD have been promising. Expand
Acute retinal pigment epithelial tear following intravitreal bevacizumab (Avastin) injection for occult choroidal neovascularisation secondary to age related macular degeneration
Retinal pigment epithelium (RPE) tears are well recognised complications of pigment epithelial detachments (PED) in age related macular degeneration (AMD) and may arise spontaneously after trauma,Expand
Retinal pigment epithelium tear after intravitreal bevacizumab for exudative age-related macular degeneration.
TLDR
Intravitreal injections of bevacizumab may be followed by a tear of the retinal pigment epithelium in eyes with exudative AMD and a retinal colour blindness detachment. Expand
...
1
2
3
4
5
...